Phase 2 Study Evaluating Safety and Effects of WIN378 in Adults with Moderate to Severe COPD

What this Trial Is About

Researchers are evaluating the safety, tolerability, and how the body processes different doses of WIN378, a long-acting medicine, in adults with moderate to severe chronic obstructive pulmonary disease COPD. WIN378 works by blocking a protein called TSLP that causes lung inflammation, which may affect COPD symptoms and control. This Phase 2a study is randomized, double-blind, and placebo-controlled to better understand WIN378s effects in this patient group. Participants will receive subcutaneous injections of WIN378 at two different doses or a placebo over a 24-week treatment period while continuing their standard COPD therapy. The study follows a parallel design and includes multiple centers. Researchers will monitor participants throughout the treatment and for safety until week 36. During the trial, participants will undergo various assessments including lung function tests, blood and exhaled breath analyses for inflammation markers, vital signs, body measurements, and laboratory tests. The study will also track adverse events, monitor drug levels in the blood, and check for immune responses to WIN378. The total participation time spans approximately 36 weeks, covering treatment and follow-up evaluations.

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)